These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3147888)

  • 1. Development of Pseudomonas aeruginosa resistance to norfloxacin during therapy.
    Rowen RC; Mullenix TA; Arroyo JC; Voris JC
    Drug Intell Clin Pharm; 1988 Oct; 22(10):773-6. PubMed ID: 3147888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
    Leigh DA; Emmanuel FX
    J Antimicrob Chemother; 1984 May; 13 Suppl B():85-8. PubMed ID: 6234280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.
    Chamberland S; Bayer AS; Schollaardt T; Wong SA; Bryan LE
    Antimicrob Agents Chemother; 1989 May; 33(5):624-34. PubMed ID: 2502066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers.
    Cruciani M; Monzillo V; Navarra A; Tinelli C; Concia E
    Drugs Exp Clin Res; 1988; 14(8):533-7. PubMed ID: 3150350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.
    Ogle JW; Reller LB; Vasil ML
    J Infect Dis; 1988 Apr; 157(4):743-8. PubMed ID: 3126247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norfloxacin: clinical pharmacology and clinical use.
    Rowen RC; Michel DJ; Thompson JC
    Pharmacotherapy; 1987; 7(4):92-110. PubMed ID: 3317294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to fluoroquinolones in Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Rydberg J; Larsson C; Miörner H
    Scand J Infect Dis; 1994; 26(3):317-20. PubMed ID: 7939432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones.
    Daikos GL; Lolans VT; Jackson GG
    Antimicrob Agents Chemother; 1988 May; 32(5):785-7. PubMed ID: 3134852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt.
    Gad GF; el-Domany RA; Ashour HM
    J Urol; 2008 Jul; 180(1):176-81. PubMed ID: 18499192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carbapenem resistance in Pseudomonas aeruginosa isolated from urine cultures: prevalence and risk factors].
    Álvarez-Otero J; Lamas-Ferreiro JL; González-González L; Rodríguez-Conde I; Fernández-Soneira MJ; Arca-Blanco A; Bermúdez-Sanjurjo JR; de la Fuente-Aguado J
    Rev Esp Quimioter; 2017 Jun; 30(3):183-194. PubMed ID: 28440605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis.
    Reidy JJ; Hobden JA; Hill JM; Forman K; O'Callaghan RJ
    Cornea; 1991 Jan; 10(1):25-8. PubMed ID: 1902152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials.
    Nix DE; DeVito JM
    Clin Pharm; 1987 Feb; 6(2):105-17. PubMed ID: 3311572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug resistance and floral distribution of Pseudomonas aeruginosa].
    Jia CY
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1990 Sep; 6(3):170-3, 236. PubMed ID: 2125852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug-resistance patterns of clinical isolates of Pseudomonas aeruginosa in regard to their lipopolysaccharide-chain sizes].
    Hasegawa M; Kobayashi I; Saika T; Nishida M
    Kansenshogaku Zasshi; 1996 Jun; 70(6):605-12. PubMed ID: 8741710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of urinary pathogens to quinolones compared to other antimicrobial agents.
    Osman LM; Sabbour MS; el-Baz F
    Chemioterapia; 1987 Jun; 6(2 Suppl):147-8. PubMed ID: 3151335
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
    DiVincenzo CA; Shatzer KL; Venezio FR
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):13S-16S. PubMed ID: 2507220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Norfloxacin: a broad-spectrum quinolone for superficial eye infections].
    Grosset J
    Pathol Biol (Paris); 1990 Sep; 38(7):735-41. PubMed ID: 2235090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection.
    Schaeffer AJ; Anderson RU
    Urology; 1992 Nov; 40(5):446-9. PubMed ID: 1441044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary study on norfloxacin in pulmonary Pseudomonas aeruginosa infections].
    Vercelloni M; Cogo R; Furcolo F; Di Franco G; Rosaschino F
    G Ital Chemioter; 1985; 32(2):489-91. PubMed ID: 3833592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.